Bhubaneswar: National Technical Advisory Group on Immunization (NTAGI) has approved Serum Institute of India’s COVID-19 vaccine Covovax for the 12-17 age group, sources told news agency ANI on Friday.
Notably, an expert panel of the country’s central drug authority recommended granting emergency use authorisation (EUA) to Covovax for this age group subject to certain conditions, on March 9. Subsequently, the Pune-based firm started to pursue regulatory permissions and its protocol.
Covovax has been developed through a technology transfer protocol from Novavax, which already has approval from the European medicines agency for conditional marketing authorisation.
India began inoculating children aged 12-14 on March 16 with Biological E’s Corbevax.
Comments are closed.